Diane L. Reidy-Lagunes, Efsevia Vakiani, Michal F. Segal, Ellen M. Hollywood, Laura H. Tang, David B. Solit, M. Catherine Pietanza, Marinela Capanu and Leonard B. Saltz A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors Cancer 118
Version of Record online: 21 MAR 2012 | DOI: 10.1002/cncr.27459
Well-differentiated neuroendocrine tumors (NETs) respond to somatostatin analogs and mammalian target of rapamycin inhibition, and preclinical studies suggest that these agents exhibit their antitumor activity through the inhibition of upstream type-1 insulin-like growth factor (IGF-1)-dependent signaling. In this phase 2 study, the authors use a humanized IGF-1 receptor monoclonal antibody (MK-0646) as a therapeutic approach in well-differentiated NETs (carcinoid tumors and pancreatic NETs), but they fail to demonstrate clinical benefit.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field